SCHEMBL21362086

SCHEMBL21362086

CCCC[S@+]([O-])N[C@@H](C)c1cc(=O)n(C)cc1-c1cc(N)c(Cl)cc1C(=O)c1ccc(F)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.34
CNR2 P34972 1/20 0.31
HTR4 Q13639 1/20 0.30
MAPK14 Q16539 1/20 0.30
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
HTR1A P08908 1/20 0.30
ADRA2A P08913 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
CYP2C9 P11712 1/20 0.30
ADRA2B P18089 1/20 0.30
HTR2C P28335 1/20 0.30
SLC6A4 P31645 1/20 0.30
CYP2C19 P33261 1/20 0.30
DRD3 P35462 1/20 0.30
HTR2B P41595 1/20 0.30
KMT2A Q03164 1/20 0.30
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21362105 0.87 BRD4 (0.32) BRD4LMNAKMT2A
SCHEMBL21362078 0.87 BRD4 (0.36) BRD4LMNAKMT2A
SCHEMBL21362174 0.85 BRD4 (0.33) BRD4HTR4MAPK14LMNAKMT2A
SCHEMBL21362080 0.83 BRD4 (0.42) BRD4CNR2
SCHEMBL21362152 0.83 BRD4 (0.37) BRD4CNR2LMNAKMT2A
SCHEMBL21362176 0.82 BRD4 (0.35) BRD4CNR2
SCHEMBL21362224 0.82 BRD4 (0.35) BRD4LMNAKMT2A
SCHEMBL21362104 0.82 CNR2 (0.32) BRD4CNR2
SCHEMBL21362258 0.82 BRD4 (0.37) BRD4LMNAKMT2A
SCHEMBL21362018 0.81 BRD4 (0.44) BRD4CNR2KMT2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 BRD4 7/4885CNR2 503/4885HTR4 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.